3 Healthcare And Biotech Stocks – LCT, SCU and AGH

In the latest scientific scorecard Australia is in the top 5 global economies in the world. For the fifth consecutive year Australia’s health care and biotechnology sector continues to show healthy performance. Despite of the challenges there has been generally positive sentiment and the industry is expected to grow to $8B in revenue over the current year. Even in the Federal Budget the Government announced $500M Genomics Health Futures Mission which included technology development, new clinical trials and greater community education.

LIVING CELL TECHNOLOGIES LIMITED (ASX:LCT) – Revenue and other income decreased from $1,166,624 to $879,519. Net assets of the consolidated entity have decreased from $7,518,340 to $7,135,323 mainly due to reduced receivable, while cash and cash equivalents have decreased from $7,530,033 to $6,861,663 as at June 30, 2018. Primarily due to the sale during the year, loss after income tax from continuing operations has decreased to a loss of $(374,492) as at June 30, 2018 from a loss of $(4,090,257) in the year ended 30 June 2017. The earnings per share of the company is at -0.001 AUD reflecting a negative profit. The stock of Living Cell Limited has risen 43.902% traded at a market price of $0.059, as at October 19, 2018, and the stock has witnessed a year to date performance change of a 64.00%. Â

STEMCELL UNITED LIMITED (ASX:SCU) – The cash and cash equivalent at the end of the quarter was around $1,086,365 that will be used to support business operations, as per the latest quarterly update report. The group recorded a reduced loss of $3,353,398 as compared to the 2017 loss of $3,631,079 against an increased revenue of $290,680 compared to 2017 of $31,619. No dividends were paid or declared since the start of the financial year or No recommendation for payment of dividends has been made. The company has no debt as at June 30, 2018. The stock has a negative earnings per share of -0.008 AUD restricting profits of the company. The stock of StemCell Limited has risen 17.241% traded at a market price of $0.034, as at October 19, 2018, and the stock has witnessed a year to date performance change of a 15.08%.

ALTHEA GROUP HOLDINGS LIMITED (ASX:AGH) – Majorly supported by institutional investors and current strategic shareholder Aphria Inc. the company raised $19.65m in heavily oversubscribed Initial Public Offer. After the generation of sales revenue from May 2018, the company has achieved the first stage of its business plan. The loss of the company for the financial period after providing for tax amounted $1,871,585. No dividends were paid or declared since the start of the financial period. The cash at bank as at the end of June 30, 2018 was of $2,300,335 with no significant debt. The stock of Athea Group Limited has fallen -3.883% traded at a market price of $0.495, as at October 19, 2018, and the stock has witnessed a year to date performance change of -8.04%.

Daily Price chart for LCT, SCU, AGH; Source: Thomson Reuters.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.

Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.